Medicare Enrolled
Dr. Bradley Ekstrand, M.D., PH.D.
Hematology & Oncology · San Mateo, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ekstrand from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ekstrand?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ekstrand
Dr. Bradley Ekstrand is a hematology & oncology specialist in San Mateo, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ekstrand performed 40,922 Medicare services across 1,496 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ekstrand received a total of $1,237 from 19 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ekstrand is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 17% volume in CA
$1,237 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,922
Medicare services
Top 17% in CA for hematology & oncology
1,496
Unique beneficiaries
$31
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,154 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 17,800 | $43 | $283 |
| Anti-nausea injection (aprepitant) | 8,710 | $1 | $27 |
| Denosumab injection (Prolia/Xgeva) | 7,200 | $18 | $145 |
| Anti-nausea injection (ondansetron/Zofran) | 1,012 | $0 | $3 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
913 | $2 | $54 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
549 | $112 | $577 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
539 | $16 | $140 |
| Pegfilgrastim-bmez biosimilar injection, 0.5 mg An injection of pegfilgrastim-bmez, a biosimilar medication, administered at a dose of 0.5 mg. |
456 | $80 | $1,838 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
429 | $139 | $1,087 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 406 | $134 | $5,575 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
390 | $2 | $61 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
354 | $163 | $773 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
338 | $13 | $139 |
| 5% dextrose/water (500 ml = 1 unit) | 251 | $1 | $53 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
194 | $29 | $160 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
148 | $68 | $487 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
145 | $29 | $209 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
142 | $33 | $318 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
130 | $29 | $169 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
98 | $71 | $383 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
91 | $1 | $20 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
91 | $7 | $339 |
| New patient office visit, complex (60-74 min) | 90 | $200 | $1,085 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
77 | $58 | $425 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
68 | $107 | $551 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
48 | $156 | $1,067 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
42 | $71 | $393 |
| Prolonged inpatient or observation care, each additional 15 minutes This code is used for prolonged hospital inpatient or observation care services that extend beyond the total time required for the primary evaluation and management service. It covers each additional 15-minute increment of time spent by the provider. |
42 | $27 | $164 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
40 | $27 | $176 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
30 | $37 | $346 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
25 | $13 | $92 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
22 | $34 | $355 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
20 | $30 | $206 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
18 | $167 | $1,542 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
14 | $63 | $428 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.8% high complexity
90.5% medium
5.7% routine
Industry Payment Transparency
Open Payments through 2023 ↗$1,237
Total received (2018-2023)
Avg $206/year across 6 years
Bottom 37% in CA for hematology & oncology
19
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$819 (66.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$417 (33.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$200
2022
$26
2021
$252
2020
$84
2019
$204
2018
$471
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$146
PFIZER INC.
$31
PharmaEssentia USA Corporation
$22
Top 3 companies account for 100.0% of 2023 payments
All-time payments by company (2018-2023) ›
PFIZER INC.
$345
Genentech USA, Inc.
$299
Janssen Biotech, Inc.
$151
E.R. Squibb & Sons, L.L.C.
$73
Seattle Genetics, Inc.
$55
Bayer HealthCare Pharmaceuticals Inc.
$47
Novartis Pharmaceuticals Corporation
$47
Incyte Corporation
$25
MEDIVATION FIELD SOLUTIONS LLC
$23
PharmaEssentia USA Corporation
$22
Celgene Corporation
$21
Spectrum Pharmaceuticals Inc.
$21
Merck Sharp & Dohme Corporation
$19
AbbVie, Inc.
$19
AMAG Pharmaceuticals, Inc.
$18
Eisai Inc.
$13
EISAI INC.
$13
Lexicon Pharmaceuticals, Inc.
$13
Gilead Sciences, Inc.
$12
Top 3 companies account for 64.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Aliqopa · BESREMI · CERTUS 140 MICROWAVE ABLATION SYSTEM · DARZALEX · ERLEADA · FERAHEME · Folotyn · GAZYVA · Halaven · IBRANCE · IMBRUVICA · INLYTA · JAKAFI · KEYTRUDA · KISQALI · LORBRENA · Lenvima · Lunsumio · Revlimid · SPRYCEL · TECENTRIQ · Venclexta · XALKORI · XTANDI · Xermelo · Xofigo
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (66%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
149
Per 100K population
20.0
County median income
$156,000
Nearest hospital
SAN MATEO MEDICAL CENTER
1.4 mi
1.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ekstrand is a mixed practice specialist, with above-average Medicare volume (top 17% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ekstrand experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Ekstrand performed 17,800 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ekstrand receive payments from pharmaceutical companies?
Yes. Dr. Ekstrand received a total of $1,237 from 19 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ekstrand's costs compare to other hematology & oncology specialists in San Mateo?
Dr. Ekstrand's average Medicare payment per service is $31. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ekstrand) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in San Mateo
Browse hematology & oncology specialists in San Mateo ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology